UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’

AbbVie reported that all three dose regimens of its drug zumilokibart met the primary endpoint in a Phase 2 study for atopic dermatitis, with the mid-dose showing early improvements. The drug, an anti-IL-13 monoclonal antibody, aims to offer extended dosing intervals in a crowded market valued at $20.69 billion in 2025. Secondary endpoints also supported the mid- and high-dose regimens, with safety profiles consistent with similar drugs.

AbbVie reported that all three doses of zumilokibart, its anti-IL-13 monoclonal antibody, met the primary endpoint in a Phase 2 study for atopic dermatitis. The study involved adults with moderate-to-severe atopic dermatitis.

AbbVie (ABBV) announced positive Phase 2 results for zumilokibart, a treatment for moderate to severe atopic dermatitis, at the EADV 2026 Congress. All three dose regimens met the primary endpoint, showing significant improvements in EASI-75 response rates versus placebo at Week 16. The mid-dose regimen was selected for Phase 3 development. Zumilokibart is a monoclonal antibody targeting IL-13.

AbbVie (ABBV) will present 60 research abstracts at the 2026 EADV Congress, including three late-breaking reports. The presentations cover data on approved therapies risankizumab and upadacitinib, and investigational compounds lutikizumab and zumilokibart. Key studies include 52-week upadacitinib data for alopecia areata, 16-week zumilokibart results for atopic dermatitis, and lutikizumab data for hidradenitis suppurativa.

AbbVie (ABBV) will present 60 abstracts at the 2026 EADV Congress, showcasing data on its dermatology portfolio, including approved therapies SKYRIZI (risankizumab) and RINVOQ (upadacitinib), and investigational compounds lutikizumab and zumilokibart. The data covers various skin diseases like alopecia areata, atopic dermatitis, and psoriasis, highlighting efficacy and safety across diverse patient populations.

A US judge ruled that Celgene, Teva, AbbVie, and others must face antitrust claims over alleged market monopolization of Revlimid. The judge found plausible evidence of an anticompetitive agreement between Celgene and Natco to delay a generic version, allowing high prices.